Summary: Retatrutide, an investigational GLP-1/GIP/glucagon triple agonist, most commonly causes gastrointestinal side effects, and no direct human fertility data currently exist, though indirect reproductive benefits via weight loss are plausible
Providers who can prescribe both have more tools to work with, and patients dont have to restart their care somewhere else if their treatment needs to evolve
Cardiovasc Diabetol 20(1):205
In some cases, it can be incorporated as a treatment for weight loss , but it must be under medical recommendation and in cases of obesity or overweight
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fractio
Multimodal imaging in deferasirox-mediated retinopathy